CJC-1295 (with DAC)
Growth hormone In trials Human trials
Also called CJC-1295, DAC:GRF, Drug Affinity Complex GRF
The original CJC-1295, and the reason the naming is a mess: this is modified GRF (1-29) with a linker bolted on that grabs hold of albumin in the blood. Albumin circulates for weeks, so the peptide goes from lasting about half an hour to lasting about a week.
Evidence at a glance
- Evidence
- Human trials — Studied in people
- Status
- Reached clinical trials
- Dosing
- A dose has been tested in humans
Sustained IGF-1 elevation is the whole point of the DAC, and also the concern: the body's pulsatile pattern exists for a reason, and continuous elevation may blunt the pituitary's own response over time. Development was discontinued after early trials rather than completed, so long-term safety was never established.
What studies report
- Sustained increases in growth hormone and IGF-1 for over a week after a single dose in phase 1 studies
- Dose-dependent IGF-1 elevation maintained with weekly or twice-weekly injection
- Development was discontinued after early-phase trials
How it works
A maleimidopropionic acid group forms a covalent bond with cysteine-34 on albumin, the most abundant protein in plasma. The peptide then circulates with it, giving a half-life of roughly 6–8 days instead of under 30 minutes — but producing a continuous elevation rather than the pulses the body normally releases.
Where it acts
Pituitary glandThe library groups this compound under Growth hormone. The diagram shows that target, not every tissue it reaches.
Illustrated
AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
In practice Unapproved use
- Chosen over the no-DAC version for convenience — one or two injections a week instead of daily
- Criticised within the community for flattening the natural GH pulse, which is the argument for using the no-DAC form instead
- The two are constantly confused, and vendors frequently mislabel one as the other
Science hasn't caught up: Phase 1 data is real and shows the half-life works as designed. Whether a continuous elevation is better or worse than preserved pulses for any actual outcome was never settled — development stopped first.
Reported real-world use, not evidence and not a recommendation.
Dosing
What was tested Evidence
- 30–60 mcg/kg, subcutaneousSingle dose, followed for 2+ weeksPhase 1 in healthy adults→ GH rose 2–10 fold; IGF-1 stayed elevated for 9–11 days
What people report using Not evidence
- 1–2 mg weekly or split twice weekly
- Often paired with a ghrelin-receptor peptide to add a pulse on top of the baseline
Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.
Status: Reached phase 1 and 2 trials. Development discontinued; never approved.
- Route
- Subcutaneous injection, weekly or twice weekly
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, conjugated to a maleimidopropionic acid DAC linker
- Formula
- C165H269N47O46
- Molecular weight
- 3647.2 g/mol
- CAS
- 446262-90-4
- Available as
- 2 mg vials
Search PubMed for CJC-1295 (with DAC) → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Compared with
Side-by-side pages for the compounds this one is most often confused with or taken alongside.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.